Online inquiry

IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12680MR)

This product GTTS-WQ12680MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FZD1&FZD2&FZD5&FZD7&FZD8 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003505.2; NM_001466.4; NM_003468.4; NM_003507; NM_031866.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8321; 2535; 7855; 8324; 8325
UniProt ID Q9UP38; Q14332; Q13467; O75084; Q9H461
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12680MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13947MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ14023MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ11488MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ3823MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ8969MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ7464MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ4668MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ5254MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CB-6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW